Trial Profile
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-531 Administered Orally to Healthy Japanese Male Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Jan 2010
Price :
$35
*
At a glance
- Drugs Cerlapirdine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Wyeth
- 26 Jul 2007 New trial record.